Donate Toggle Menu

Dr. McDermott on Single-Agent Pembrolizumab in Advanced RCC

In this video, David F. McDermott, MD, director of the Biologic Therapy Program at Beth Israel Deaconess Medical Center, discusses the use of single-agent pembrolizumab (Keytruda) in the treatment of patients with advanced non–clear cell renal cell carcinoma (RCC).

New therapeutic target found for aggressive pediatric cancers with few treatment options

Researchers at the University of Texas MD Anderson Cancer Center recently discovered a new therapeutic target for malignant rhabdoid tumors (MRT). MRT is a rare pediatric cancer that commonly starts in the kidneys. Dr. Pavlos Msaouel, who was a 2017 Conquer Cancer Foundation Young Investigator Award recipient supported by the Kidney Cancer Association, was involved in this breakthrough finding.

First-line Pembrolizumab Monotherapy

Keynote 427 Cohort B results demonstrate promising anti-tumor activity with first line pembrolizumab monotherapy in non-clear cell advanced RCC.

ASCO GU 2019: Analysis of Overall Survival Based on Early Tumor Shrinkage in the Phase III METEOR Study of Cabozantinib versus Everolimus in Advanced Renal Cell Carcinoma

During the Rapid Abstract Session on Renal Cell Cancer at the Annual ASCO GU 2019 meeting in San Francisco, CA, Dr. Duran presented on the analysis of overall survival (OS) based on early tumor shrinkage in the phase III METEOR study of cabozantinib (cabo) versus everolimus (eve) in advanced renal cell carcinoma (RCC).

1 3 4 5 6 7 8

Media Contact

Email Radha Chitale with media inquiries. Please include your name, outlet, topic, deadline, and contact details.